Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs

Area of Science:

• Cardiovascular pharmacology
• Metabolic effects of antihypertensives
• Endothelial function

Background:

• The ASCOT-BPLA study indicated that atenolol+bendroflumethiazide therapy led to more adverse cardiovascular outcomes and diabetes development than amlodipine+perindopril.
• These differences were not solely attributable to blood pressure changes, suggesting other drug-specific mechanisms.

Purpose of the Study:

• To investigate the distinct vascular and metabolic effects of various antihypertensive drug classes.
• To determine if these differential effects explain the varying clinical outcomes observed in previous studies.

Main Methods:

• A randomized, single-blind, placebo-controlled study involving 6 arms.
• Patients received placebo or one of five antihypertensive drugs (atenolol, amlodipine, hydrochlorothiazide, ramipril, candesartan) daily for 8 weeks.
• Systolic blood pressure, lipid profiles, flow-mediated dilation (FMD), adiponectin, insulin sensitivity, leptin, and resistin levels were assessed.

Main Results:

• Atenolol, amlodipine, and candesartan reduced systolic blood pressure more than ramipril.
• Atenolol and thiazide therapies increased triglycerides; amlodipine increased HDL cholesterol.
• Ramipril and candesartan improved FMD, adiponectin, and insulin sensitivity more than atenolol or thiazides.
• Amlodipine increased adiponectin and decreased resistin more than atenolol.
• Ramipril, candesartan, and amlodipine decreased leptin more than atenolol or thiazides.

Conclusions:

• Antihypertensive medications exhibit differential effects on endothelial function.
• Distinct impacts on plasma adipocytokine levels (adiponectin, leptin, resistin) were observed among different drug classes.
• These vascular and metabolic variations may contribute to the differing clinical outcomes associated with these therapies.